CommentOuter-membrane-vesicle vaccines: old but not forgotten
References (7)
- et al.
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
Lancet
(2007) - et al.
From tailor-made to ready-to-wear meningococcal B vaccines: a longitudinal study of a clonal meningococcal B outbreak
Lancet Infect Dis
(2011) Serological relationships among meningococci
Bacteriol Rev
(1953)
Cited by (9)
Neisseria meningitidis
2023, Molecular Medical Microbiology, Third EditionMeningococcal Infections in Children and Adolescents: Update and Prevention
2020, Advances in PediatricsCitation Excerpt :Serogroup B N meningitidis is also a leading cause of meningococcal disease in infants, young children, and adolescents in many countries [6,13]. Because the serogroup B polysaccharide resembles the human neural cell adhesion molecule and other human antigens, it is poorly immunogenic and carries a potential risk of autoimmunity [2,69]. Therefore, attention focused on other semiconserved surface proteins for use as vaccine antigens.
Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: Lessons of the Normandy campaign
2017, VaccineCitation Excerpt :Since then, multi-component protein-based vaccines that offer broad coverage against group B N. meningitidis have been developed. Such new vaccines do not necessarily make former OMV meningococcal vaccines obsolete [3]. The new multi-component protein-based vaccines do not cover all circulating serogroup B isolates.
Neisseria meningitidis
2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious DiseasesNeisseria meningitidis
2014, Molecular Medical MicrobiologyPrevention of serogroup B meningococcal disease
2012, The Lancet